1
40
26
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1136/bcr-2015-209928" target="_blank" rel="noreferrer noopener">http://doi.org/10.1136/bcr-2015-209928</a>
Volume
2015
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Catastrophic chest pain: blinded by cardiopulmonary disease.
Publisher
An entity responsible for making the resource available
BMJ case reports
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-07
Subject
The topic of the resource
*Decompression; *Laminectomy; *Magnetic Resonance Imaging; Administration; Anti-Bacterial Agents/*administration & dosage; Chest Pain/diagnosis/drug therapy/*etiology; Coronary Disease; Diabetic Foot; Drug-Eluting Stents/*adverse effects; Epidural Abscess/*etiology/surgery; Humans; Hypertension; Intravenous; Male; Middle Aged; Nafcillin/*administration & dosage; Osteomyelitis/*complications/diagnosis/drug therapy; Surgical; Treatment Outcome
Creator
An entity primarily responsible for making the resource
Barreiro Timothy John; Asiimwe Denis D; Gemmel David; Brine Patrick
Description
An account of the resource
A 53-year-old man with a history of diabetic foot ulcer, osteomyelitis, coronary artery disease, hypertension and hyperlipidaemia, presented with chest pain of 3 weeks duration. Eleven days earlier, the patient had had a drug-eluting stent (DES) placed in a branch of the right coronary artery (RCA) after similar chest pain, leading to the findings of a positive nuclear stress test. Since discharge, he was not compliant with taking clopidegrel (Plavix), a concern for in-stent thrombosis with recurrent myocardial ischaemia; but work up was negative and medications were restarted. Within 24 h of admission, he developed bilateral flaccid leg weakness, urine retention and loss of sensation from the umbilicus level down. MRI revealed a T4-T6 epidural abscess. Emergent decompression laminectomy and abscess drainage was completed. Neurological symptoms improved hours after surgery with complete resolution of sensory deficits. Cultures grew Streptococcus sp., treated with intravenous nafcillin for 8 weeks. He regained leg strength with continued improvement seen in rehabilitation.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1136/bcr-2015-209928" target="_blank" rel="noreferrer noopener">10.1136/bcr-2015-209928</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Decompression
*Laminectomy
*Magnetic Resonance Imaging
2015
Administration
Anti-Bacterial Agents/*administration & dosage
Asiimwe Denis D
Barreiro Timothy John
BMJ case reports
Brine Patrick
Chest Pain/diagnosis/drug therapy/*etiology
Coronary Disease
Department of Internal Medicine
Diabetic Foot
Drug-Eluting Stents/*adverse effects
Epidural Abscess/*etiology/surgery
Gemmel David
Humans
Hypertension
Intravenous
Male
Middle Aged
Nafcillin/*administration & dosage
NEOMED College of Medicine
Osteomyelitis/*complications/diagnosis/drug therapy
Surgical
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.clinthera.2011.08.005" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.clinthera.2011.08.005</a>
Pages
1322–1330
Issue
9
Volume
33
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Assessment of the Clinical Use of Intravenous and Oral N-Acetylcysteine in the Treatment of Acute Acetaminophen Poisoning in Children: A Retrospective Review.
Publisher
An entity responsible for making the resource available
Clinical Therapeutics
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-09
Subject
The topic of the resource
United States; Patient Selection; Medical Records; Descriptive Statistics; Retrospective Design; Intravenous; Administration; Oral; Cost Benefit Analysis; Acetaminophen – Adverse Effects; Acetylcysteine – Therapeutic Use; Overdose – Drug Therapy; Poisoning – Drug Therapy
Creator
An entity primarily responsible for making the resource
Blackford Martha G; Felter Thomas; Gothard M David; Reed Michael D
Description
An account of the resource
Abstract: Background: N-acetylcysteine (NAC) is the most effective therapy for acetaminophen (APAP) toxicity and is currently available for oral and intravenous (IV) administration. Although both routes are effective, use of the IV formulation has been increasing since becoming available in the United States in 2004, raising questions about cost/benefit comparisons between the 2 formulations. Decreased length of treatment and hospital stay have been used to justify the use of IV NAC; however, some patients may receive extended therapy of either NAC regimen. Objective: This retrospective review assessed the clinical use of oral and IV NAC in pediatric patients with APAP intoxication from June 1, 2004 through May 31, 2008. Methods: Electronic medical charts for patients aged ≤21 years were identified with International Classification of Diseases, Ninth Revision (ICD-9) codes for APAP overdose. Descriptive statistics were used to describe the overall patient population and route of NAC administration. The primary outcome variable was the length of treatment with IV and oral NAC therapy. Results: A total of 62 charts for patients with APAP toxicity were reviewed; 37 patients (60%) received IV NAC and 25 patients (40%) received oral NAC. The average lengths of treatment and stay for IV dosing were 23.5 hours (range, 17.6–54.9 hours) and 1.6 days (range, 1–3 days), respectively; those for oral dosing were 69.5 hours (range, 33–133 hours) and 1.95 days (range, 1–5 days), respectively. Of 16 patients who received oral NAC and were admitted for \textless3 days, 14 were transferred to an inpatient psychiatric unit and completed the 72-hour therapy. A total of 3 patients received extended NAC dosing—2 with IV dosing and 1 with oral dosing. Conclusions: Based on our review, the majority of patients received recommended dosing of NAC therapy; however, 3 patients received extended NAC therapy. Patient-specific factors should be considered when assessing whether NAC therapy should be extended and if one route of administration may be preferred. ClinicalTrials.gov identifier: NCT00725179.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.clinthera.2011.08.005" target="_blank" rel="noreferrer noopener">10.1016/j.clinthera.2011.08.005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
Acetaminophen – Adverse Effects
Acetylcysteine – Therapeutic Use
Administration
Blackford Martha G
Clinical Therapeutics
Cost Benefit Analysis
Descriptive Statistics
Felter Thomas
Gothard M David
Intravenous
Medical Records
Oral
Overdose – Drug Therapy
Patient Selection
Poisoning – Drug Therapy
Reed Michael D
Retrospective Design
United States
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1152/ajprenal.00510.2014" target="_blank" rel="noreferrer noopener">http://doi.org/10.1152/ajprenal.00510.2014</a>
Pages
F92–F100
Issue
2
Volume
308
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Mesenchymal stem cells and their secretome partially restore nerve and urethral function in a dual muscle and nerve injury stress urinary incontinence model.
Publisher
An entity responsible for making the resource available
American journal of physiology. Renal physiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-01
Subject
The topic of the resource
*Mesenchymal Stem Cell Transplantation; Animals; Conditioned; Culture Media; elastin; external urethral sphincter; Female; Injections; Intraperitoneal; Intravenous; Mesenchymal Stem Cells/metabolism; paracrine action; Parturition; pudendal nerve; Pudendal Nerve/injuries/*physiology; Rats; Sprague-Dawley; Stress/etiology/*prevention & control; Urethra/injuries/*physiology; urinary incontinence; Urinary Incontinence
Creator
An entity primarily responsible for making the resource
Deng Kangli; Lin Dan Li; Hanzlicek Brett; Balog Brian; Penn Marc S; Kiedrowski Matthew J; Hu Zhiquan; Ye Zhangqun; Zhu Hui; Damaser Margot S
Description
An account of the resource
Childbirth injures muscles and nerves responsible for urinary continence. Mesenchymal stem cells (MSCs) or their secretome given systemically could provide therapeutic benefit for this complex multisite injury. We investigated whether MSCs or their secretome, as collected from cell culture, facilitate recovery from simulated childbirth injury. Age-matched female Sprague-Dawley rats received pudendal nerve crush and vaginal distension (PNC+VD) and a single intravenous (iv) injection of 2 million MSCs or saline. Controls received sham injury and iv saline. Additional rats received PNC+VD and a single intraperitoneal (ip) injection of concentrated media conditioned by MSCs (CCM) or concentrated control media (CM). Controls received a sham injury and ip CM. Urethral and nerve function were assessed with leak point pressure (LPP) and pudendal nerve sensory branch potential (PNSBP) recordings 3 wk after injury. Urethral and pudendal nerve anatomy were assessed qualitatively by blinded investigators. Quantitative data were analyzed using one-way ANOVA and Holm-Sidak post hoc tests with P \textless 0.05 indicating significant differences. Both LPP and PNSBP were significantly decreased 3 wk after PNC+VD with saline or CM compared with sham-injured rats, but not with MSC or CCM. Elastic fiber density in the urethra increased and changed in orientation after PNC+VD, with a greater increase in elastic fibers with MSC or CCM. Pudendal nerve fascicles were less dense and irregularly shaped after PNC+VD and had reduced pathology with MSC or CCM. MSC and CCM provide similar protective effects after PNC+VD, suggesting that MSCs act via their secretions in this dual muscle and nerve injury.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1152/ajprenal.00510.2014" target="_blank" rel="noreferrer noopener">10.1152/ajprenal.00510.2014</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Mesenchymal Stem Cell Transplantation
2015
American journal of physiology. Renal physiology
Animals
Balog Brian
Conditioned
Culture Media
Damaser Margot S
Deng Kangli
elastin
external urethral sphincter
Female
Hanzlicek Brett
Hu Zhiquan
Injections
Intraperitoneal
Intravenous
Kiedrowski Matthew J
Lin Dan Li
Mesenchymal Stem Cells/metabolism
paracrine action
Parturition
Penn Marc S
pudendal nerve
Pudendal Nerve/injuries/*physiology
Rats
Sprague-Dawley
Stress/etiology/*prevention & control
Urethra/injuries/*physiology
Urinary Incontinence
Ye Zhangqun
Zhu Hui
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/PEC.0b013e31827b227e" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/PEC.0b013e31827b227e</a>
Pages
13–16
Issue
1
Volume
29
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Efficacy of intravenous lidocaine to reduce pain and distress associated with propofol infusion in pediatric patients during procedural sedation.
Publisher
An entity responsible for making the resource available
Pediatric emergency care
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-01
Subject
The topic of the resource
Female; Male; Child; Infant; Prospective Studies; Pain Measurement; Analysis of Variance; Placebos; Injections; Human; Chi Square Test; Preschool; Intravenous; Anesthetics; Treatment Outcomes; Double-Blind Studies; Hypnotics and Sedatives – Administration and Dosage; Lidocaine – Administration and Dosage; Local – Administration and Dosage; Propofol – Administration and Dosage
Creator
An entity primarily responsible for making the resource
Depue K; Christopher NC; Raed M; Forbes ML; Besunder J; Reed MD
Description
An account of the resource
BACKGROUND: Research suggests that young children experience an increased incidence and severity of discomfort during propofol infusion. Evaluations of varied interventions to reduce or eliminate this discomfort with adult subjects suggest that premedication with intravenously administered lidocaine (0.5 mg/kg) offers the best overall effectiveness. OBJECTIVE: Because this regimen's efficacy in a pediatric population is undocumented, we conducted a randomized, double-blind, placebo-controlled study to determine the effectiveness of intravenous lidocaine pretreatment to alleviate pain in pediatric subjects before propofol infusion. METHODS: Subjects (aged 2-7 years) scheduled for painless diagnostic procedures received either a saline placebo or 1 of 2 lidocaine doses before administering propofol. To capture the patient's baseline behavioral state, a trained observer administered the validated Face, Legs, Activity, Cry, Consolability Pain Assessment Scale before propofol infusion. During deep sedation induction, the sedating physician, a trained research assistant, and the patient's parent documented maximum distress using a 100-mm visual analog scale (VAS). RESULTS: Ninety-one subjects participated. We found no difference in VAS pain scores between groups pretreated with lidocaine 0.25 mg/kg, lidocaine 0.5 mg/kg, and placebo. Statistical analysis also found no interrater differences between parents, physician, or observer VAS scores. CONCLUSIONS: Our data do not support using lidocaine pretreatment to alleviate pain/discomfort in pediatric patients during propofol infusion.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/PEC.0b013e31827b227e" target="_blank" rel="noreferrer noopener">10.1097/PEC.0b013e31827b227e</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
Analysis of Variance
Anesthetics
Besunder J
Chi Square Test
Child
Christopher NC
Department of Emergency Medicine
Depue K
Double-Blind Studies
Female
Forbes ML
Human
Hypnotics and Sedatives – Administration and Dosage
Infant
Injections
Intravenous
Lidocaine – Administration and Dosage
Local – Administration and Dosage
Male
NEOMED College of Medicine
Pain Measurement
Pediatric emergency care
Placebos
Preschool
Propofol – Administration and Dosage
Prospective Studies
Raed M
Reed MD
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/bf01250672" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/bf01250672</a>
Pages
197–207
Issue
3
Volume
89
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
L-dopa infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine.
Publisher
An entity responsible for making the resource available
Journal of neural transmission. General section
Date
A point or period of time associated with an event in the lifecycle of the resource
1992
1905-6
Subject
The topic of the resource
Amphetamine/pharmacology; Animals; Chromatography; Corpus Striatum/*drug effects/metabolism; Dopamine/*metabolism; High Pressure Liquid; Infusions; Intravenous; Levodopa/*pharmacology; Male; Potassium/pharmacology; Rats; Reserpine/*pharmacology; Sprague-Dawley
Creator
An entity primarily responsible for making the resource
Dluzen D E; Kratko F T Jr
Description
An account of the resource
In the present experiment we tested the effects of L-DOPA upon dopamine (DA) efflux in vitro from superfused corpus striatal tissue fragments in medium containing reserpine. The purposes of this experiment were first, to evaluate the effects of differing infusion modes of L-DOPA upon DA efflux under conditions in which DA storage capacity has been diminished, and second, to compare this L-DOPA stimulated DA efflux with that of other putative DA secretagogues such as amphetamine and potassium. No differences were obtained in stimulated DA efflux between superfusions performed in the presence or absence of reserpine (10 microM) in the medium when L-DOPA (5 microM) was infused in a continuous (70 minute) mode during the superfusion. In contrast, a continuous infusion of either amphetamine (10 microM) or high potassium (30 mM) resulted in significantly greater stimulated DA efflux in superfusions performed with reserpine in the medium. In addition, when L-DOPA (5 microM) was administered for a brief
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/bf01250672" target="_blank" rel="noreferrer noopener">10.1007/bf01250672</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1992
Amphetamine/pharmacology
Animals
Chromatography
Corpus Striatum/*drug effects/metabolism
Dluzen D E
Dopamine/*metabolism
High Pressure Liquid
Infusions
Intravenous
Journal of neural transmission. General section
Kratko F T Jr
Levodopa/*pharmacology
Male
Potassium/pharmacology
Rats
Reserpine/*pharmacology
Sprague-Dawley
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/00019048-199802000-00005" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/00019048-199802000-00005</a>
Pages
1965–1972
Issue
9
Volume
41
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Antimicrobial agents and chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
1997
1997-09
Subject
The topic of the resource
*Levofloxacin; 80 and over; Administration; Adolescent; Adult; Aged; Anti-Infective Agents/adverse effects/*therapeutic use; Bacterial/*drug therapy/microbiology; Ceftriaxone/adverse effects/*therapeutic use; Cefuroxime/adverse effects/*analogs & derivatives/therapeutic use; Cephalosporins/adverse effects/*therapeutic use; Combination; Community-Acquired Infections/drug therapy/microbiology; Drug Therapy; Female; Humans; Injections; Intravenous; Male; Middle Aged; Ofloxacin/adverse effects/*therapeutic use; Oral; Pneumonia; Prodrugs/adverse effects/*therapeutic use; Prospective Studies; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File T M Jr; Segreti J; Dunbar L; Player R; Kohler R; Williams R R; Kojak C; Rubin A
Description
An account of the resource
Five hundred ninety patients were enrolled in a prospective, multicenter, randomized trial comparing the efficacy and safety of 7 to 14 days of levofloxacin treatment with that of ceftriaxone and/or cefuroxime axetil in the management of community-acquired pneumonia in adults. Patients received either intravenous and/or oral levofloxacin (500 mg once daily) or the comparative agents, parenteral ceftriaxone (1 to 2 g once to twice daily) and/or oral cefuroxime axetil (500 mg twice daily). Erythromycin or doxycycline could be added to the comparator arm at the investigator's discretion. The decision to use an intravenous or oral antimicrobial agent for initial therapy was made by the investigator. Clinical and microbiological evaluations were completed at the baseline, during treatment, 5 to 7 days posttherapy, and 3 to 4 weeks posttherapy. Four hundred fifty-six patients (226 given levofloxacin and 230 administered ceftriaxone and/or cefuroxime axetil) were evaluable for clinical efficacy. Streptococcus pneumoniae and Haemophilus influenzae were isolated in 15 and 12%, respectively, of clinically evaluable patients. One hundred fifty atypical pathogens were identified: 101 were Chlamydia pneumoniae, 41 were Mycoplasma pneumoniae, and 8 were Legionella pneumophila. Clinical success at 5 to 7 days posttherapy was superior for the levofloxacin group (96%) compared with the ceftriaxone and/or cefuroxime axetil group (90%) (95% confidence interval [CI] of -10.7 to -1.3). Among patients with typical respiratory pathogens who were evaluable for microbiological efficacy, the overall bacteriologic eradication rates were superior for levofloxacin (98%) compared with the ceftriaxone and/or cefuroxime axetil group (85%) (95% CI of -21.6 to -4.8). Levofloxacin eradicated 100% of the most frequently reported respiratory pathogens (i.e., H. influenzae and S. pneumoniae) and provided a \textgreater98% clinical success rate in patients with atypical pathogens. Both levofloxacin and ceftriaxone-cefuroxime axetil eradicated 100% of the S. pneumoniae cells detected in blood culture. Drug-related adverse events were reported in 5.8% of patients receiving levofloxacin and in 8.5% of patients administered ceftriaxone and/or cefuroxime axetil. Gastrointestinal and central and peripheral nervous system adverse events were the most common events reported in each treatment group. In conclusion, these results demonstrate that treatment with levofloxacin is superior to ceftriaxone and/or cefuroxime axetil therapy in the management of community-acquired pneumonia in adults.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/00019048-199802000-00005" target="_blank" rel="noreferrer noopener">10.1097/00019048-199802000-00005</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Levofloxacin
1997
80 and over
Administration
Adolescent
Adult
Aged
Anti-Infective Agents/adverse effects/*therapeutic use
Antimicrobial agents and chemotherapy
Bacterial/*drug therapy/microbiology
Ceftriaxone/adverse effects/*therapeutic use
Cefuroxime/adverse effects/*analogs & derivatives/therapeutic use
Cephalosporins/adverse effects/*therapeutic use
Combination
Community-Acquired Infections/drug therapy/microbiology
Department of Internal Medicine
Drug Therapy
Dunbar L
Female
File T M Jr
Humans
Injections
Intravenous
Kohler R
Kojak C
Male
Middle Aged
NEOMED College of Medicine
Ofloxacin/adverse effects/*therapeutic use
Oral
Player R
Pneumonia
Prodrugs/adverse effects/*therapeutic use
Prospective Studies
Rubin A
Segreti J
Treatment Outcome
Williams R R
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/jac/dkr096</a>
Pages
iii19–32
Volume
66 Suppl 3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
The Journal of antimicrobial chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-04
Subject
The topic of the resource
80 and over; 80 and Over; Aged; Bacteria; Bacteria/isolation & purification; Bacterial – Drug Therapy; Bacterial/*drug therapy; Ceftriaxone – Administration and Dosage; Ceftriaxone – Adverse Effects; Ceftriaxone/administration & dosage/adverse effects; Cephalosporins – Administration and Dosage; Cephalosporins – Adverse Effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections – Drug Therapy; Community-Acquired Infections/*drug therapy; Double-Blind Method; Double-Blind Studies; Female; Human; Humans; Infusions; Intravenous; Male; Middle Age; Middle Aged; Pneumonia; Randomized Controlled Trials; Treatment Outcome; Treatment Outcomes
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian A; Thye Dirk A
Description
An account of the resource
OBJECTIVES: Ceftaroline, the active form of the prodrug ceftaroline fosamil, is a novel cephalosporin with bactericidal activity against important pathogens associated with community-acquired pneumonia (CAP), including Streptococcus pneumoniae and common Gram-negative pathogens. FOCUS 1 is a randomized, double-blinded, Phase III study that was conducted to evaluate the efficacy and safety of ceftaroline fosamil in treating patients with CAP. The primary objective was to determine non-inferiority [lower limit of 95% confidence interval (CI) \textgreater/= -10%] in clinical cure rates achieved with ceftaroline fosamil compared with those achieved with ceftriaxone in the clinically evaluable (CE) and modified intent-to-treat efficacy (MITTE) populations. METHODS: Patients hospitalized in a non-intensive care unit setting with CAP of Pneumonia Outcomes Research Team (PORT) risk class III or IV requiring intravenous (iv) therapy were randomized (1:1) to receive 600 mg of ceftaroline fosamil iv every 12 h or 1 g of ceftriaxone iv every 24 h. Patients also received two 500 mg doses of oral clarithromycin every 12 h administered on day 1. Clinical cure, microbiological response, adverse events (AEs) and laboratory tests were assessed. FOCUS 1 registration number NCT00621504 (http://clinicaltrials.gov/ct2/show/NCT00621504). RESULTS: Of 613 enrolled patients, 298 received ceftaroline fosamil and 308 received ceftriaxone. Baseline characteristics between treatment groups were comparable. Clinical cure rates were as follows: CE population, 86.6% (194/224) for ceftaroline fosamil and 78.2% (183/234) for ceftriaxone [difference (95% CI), 8.4% (1.4, 15.4)]; and MITTE population, 83.8% (244/291) for ceftaroline fosamil and 77.7% (233/300) for ceftriaxone [difference (95% CI), 6.2% (-0.2, 12.6)]. Clinical cure rates for CAP caused by S. pneumoniae in the microbiological MITTE population were 88.9% (24/27) and 66.7% (20/30) for ceftaroline fosamil and ceftriaxone, respectively. Both agents were well tolerated, with similar rates of AEs, serious AEs, deaths and discontinuations because of an AE. The most common AEs for ceftaroline fosamil-treated patients were diarrhoea, headache, insomnia and nausea, and the most common AEs for ceftriaxone-treated patients were hypokalaemia, hypertension, nausea and diarrhoea. CONCLUSIONS: Ceftaroline fosamil demonstrated high clinical cure and microbiological response rates in hospitalized patients with CAP of PORT risk class III or IV. Ceftaroline fosamil was well tolerated, with a safety profile similar to that of ceftriaxone and consistent with the cephalosporin class. In this study, ceftaroline fosamil was an effective and well-tolerated treatment option for CAP.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/jac/dkr096" target="_blank" rel="noreferrer noopener">10.1093/jac/dkr096</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2011
80 and over
Aged
Bacteria
Bacteria/isolation & purification
Bacterial – Drug Therapy
Bacterial/*drug therapy
Ceftriaxone – Administration and Dosage
Ceftriaxone – Adverse Effects
Ceftriaxone/administration & dosage/adverse effects
Cephalosporins – Administration and Dosage
Cephalosporins – Adverse Effects
Cephalosporins/*administration & dosage/*adverse effects
Community-Acquired Infections – Drug Therapy
Community-Acquired Infections/*drug therapy
Critchley Ian A
Department of Internal Medicine
Double-Blind Method
Double-Blind Studies
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Human
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Age
Middle Aged
NEOMED College of Medicine
Pneumonia
RANDOMIZED controlled trials
Talbot George H
The Journal of antimicrobial chemotherapy
Thye Dirk A
Treatment Outcome
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1086/657313" target="_blank" rel="noreferrer noopener">http://doi.org/10.1086/657313</a>
Pages
1395–1405
Issue
12
Volume
51
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
2010-12
Subject
The topic of the resource
80 and over; Administration; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/*adverse effects; Bacterial/*drug therapy; Ceftriaxone/*administration & dosage/*adverse effects; Cephalosporins/*administration & dosage/*adverse effects; Community-Acquired Infections/drug therapy; Double-Blind Method; Female; Humans; Infusions; Intravenous; Male; Middle Aged; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Low Donald E; Eckburg Paul B; Talbot George H; Friedland H David; Lee Jon; Llorens Lily; Critchley Ian; Thye Dirk
Description
An account of the resource
BACKGROUND: Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated for the treatment of CAP in 2 randomized, double-blind, multicenter trials: Ceftaroline Community Acquired Pneumonia Trial versus Ceftriaxone in Hospitalized Patients (FOCUS) 1 and FOCUS 2. METHODS: Patients hospitalized (but not admitted to an intensive care unit) with Pneumonia Outcomes Research Team risk class III or IV CAP requiring intravenous therapy were randomized to ceftaroline 600 mg every 12 h or ceftriaxone 1 g every 24 h for 5-7 days. Patients in FOCUS 1 received 2 doses of oral clarithromycin 500 mg every 12 h on day 1. RESULTS: In the individual trials, clinical cure rates in the clinically evaluable (CE) population for ceftaroline versus ceftriaxone were as follows: FOCUS 1, 86.6% vs 78.2% (difference, 8.4%; 95% confidence interval [CI], 1.4%-15.4%); FOCUS 2, 82.1% vs 77.2% (difference, 4.9%; 95% CI, -2.5% to 12.5%). In the integrated analysis, 614 patients received ceftaroline and 614 received ceftriaxone. Of the CE patients treated with ceftaroline, 84.3% achieved clinical cure, compared with 77.7% of ceftriaxone-treated patients (difference, 6.7%; 95% CI, 1.6%-11.8%). Clinical cure rates in the modified intent-to-treat efficacy population were 82.6% versus 76.6% for ceftaroline and ceftriaxone (difference, 6.0%; 95% CI, 1.4%-10.7%). Ceftaroline and ceftriaxone were well tolerated; rates of adverse events, serious adverse events, deaths, and premature discontinuations caused by an adverse event were similar in both treatment arms. CONCLUSIONS: Ceftaroline was noninferior to ceftriaxone in the individual trials. In this integrated analysis, clinical cure rates for the ceftaroline group were numerically higher than those for the ceftriaxone group. Ceftaroline was well tolerated, with a safety profile similar to that of ceftriaxone.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1086/657313" target="_blank" rel="noreferrer noopener">10.1086/657313</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2010
80 and over
Administration
Adult
Aged
Anti-Bacterial Agents/*administration & dosage/*adverse effects
Bacterial/*drug therapy
Ceftriaxone/*administration & dosage/*adverse effects
Cephalosporins/*administration & dosage/*adverse effects
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/drug therapy
Critchley Ian
Department of Internal Medicine
Double-Blind Method
Eckburg Paul B
Female
File Thomas M Jr
Friedland H David
Humans
Infusions
Intravenous
Lee Jon
Llorens Lily
Low Donald E
Male
Middle Aged
NEOMED College of Medicine
Oral
Pneumonia
Talbot George H
Thye Dirk
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">http://doi.org/10.1185/030079904X2556</a>
Pages
1473–1481
Issue
9
Volume
20
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
Publisher
An entity responsible for making the resource available
Current medical research and opinion
Date
A point or period of time associated with an event in the lifecycle of the resource
2004
2004-09
Subject
The topic of the resource
*Levofloxacin; Administration; Adult; Anti-Bacterial Agents/*administration & dosage/economics; Bacterial/*drug therapy; Community-Acquired Infections/drug therapy; Drug Administration Schedule; Drug Costs; Female; Humans; Infusions; Intravenous; Male; Ofloxacin/*administration & dosage/economics; Oral; Pneumonia; Treatment Outcome
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Milkovich Gary; Tennenberg Alan M; Xiang Jim X; Khashab Mohammed M; Zadeikis Neringa
Description
An account of the resource
OBJECTIVE: To evaluate the time to symptom resolution and i.v.-to-p.o. transition in community-acquired pneumonia (CAP) patients treated with 750 mg or 500 mg levofloxacin. RESEARCH DESIGN: A retrospective, subset analysis of a multicenter, randomized, double-blind, controlled trial comparing 750 mg levofloxacin for 5 days to 500 mg levofloxacin for 10 days for the treatment of CAP. PATIENTS AND METHODS: A total of 528 CAP patients were included. Baseline symptoms were re-evaluated on Day 3 of therapy, and time to i.v.-to-p.o. transition was recorded for inpatients. RESULTS: For the overall population, 67.4% of patients receiving 750 mg levofloxacin had resolution of fever by Day 3 of therapy, compared to 54.6% of 500 mg treated patients (P = 0.006). Patients who started on 750 mg levofloxacin i.v. (N = 108) transitioned to p.o. in an average of 2.68 days while those starting on 500 mg i.v. (N = 124) transitioned in 2.95 days (P = 0.144). The median time for i.v.-to-p.o. switch was 2.35 days and 2.75 days for patients receiving 750 mg and 500 mg levofloxacin, respectively (P = 0.098, log rank test). By Day 3 of therapy, 68% of patients receiving the 750 mg dose had transitioned from i.v. to p.o. levofloxacin, compared with 61% of the 500 mg group (P = 0.280). The safety profiles were comparable for the two regimens. CONCLUSIONS: The 750 mg levofloxacin dose resulted in a greater proportion of patients with resolution of CAP symptoms by Day 3 when compared with 500 mg therapy. Consequently, the 750 mg regimen trended toward more rapid transition to p.o., potentially resulting in lower overall drug costs. Time to switch from i.v. to p.o. was determined by the investigators' discretion rather than a set protocol. Additionally, length of stay data was not collected in this study, which can significantly impact overall healthcare costs. Further research is required to fully understand the economic impact of the 750 mg, 5-day levofloxacin regimen.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1185/030079904X2556" target="_blank" rel="noreferrer noopener">10.1185/030079904X2556</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Levofloxacin
2004
Administration
Adult
Anti-Bacterial Agents/*administration & dosage/economics
Bacterial/*drug therapy
Community-Acquired Infections/drug therapy
Current medical research and opinion
Department of Internal Medicine
Drug Administration Schedule
Drug Costs
Female
File Thomas M Jr
Humans
Infusions
Intravenous
Khashab Mohammed M
Male
Milkovich Gary
NEOMED College of Medicine
Ofloxacin/*administration & dosage/economics
Oral
Pneumonia
Tennenberg Alan M
Treatment Outcome
Xiang Jim X
Zadeikis Neringa
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1093/cid/ciw490" target="_blank" rel="noreferrer noopener">http://doi.org/10.1093/cid/ciw490</a>
Pages
1007–1016
Issue
8
Volume
63
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia.
Publisher
An entity responsible for making the resource available
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Date
A point or period of time associated with an event in the lifecycle of the resource
2016
2016-10
Subject
The topic of the resource
*clinical trial; *community-acquired; *pneumonia; *solithromycin; *Streptococcus pneumoniae; 80 and over; Administration; Adult; Aged; Anti-Bacterial Agents/*administration & dosage/adverse effects; Bacterial; Bacterial/diagnosis/*drug therapy/*microbiology; Community-Acquired Infections/diagnosis/*drug therapy/*microbiology; Comorbidity; Drug Resistance; Female; Fluoroquinolones/*administration & dosage/adverse effects; Humans; Intravenous; Macrolides/*administration & dosage/adverse effects; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Oral; Pneumonia; Treatment Outcome; Triazoles/*administration & dosage/adverse effects
Creator
An entity primarily responsible for making the resource
File Thomas M Jr; Rewerska Barbara; Vucinic-Mihailovic Violeta; Gonong Joven Roque V; Das Anita F; Keedy Kara; Taylor David; Sheets Amanda; Fernandes Prabhavathi; Oldach David; Jamieson Brian D
Description
An account of the resource
BACKGROUND: Solithromycin, a novel macrolide antibiotic with both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia. METHODS: A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcomes Research Team [PORT] class II-IV) were randomized 1:1 to receive either intravenous-to-oral solithromycin or moxifloxacin for 7 once-daily doses. All patients received 400 mg intravenously on day 1 and were permitted to switch to oral dosing when clinically indicated. The primary objective was to demonstrate noninferiority (10% margin) of solithromycin to moxifloxacin in achievement of early clinical response (ECR) assessed 3 days after first dose in the intent-to-treat (ITT) population. Secondary endpoints included demonstrating noninferiority in ECR in the microbiological ITT population (micro-ITT) and determination of investigator-assessed success rates at the short-term follow-up (SFU) visit 5-10 days posttherapy. RESULTS: In the ITT population, 79.3% of solithromycin patients and 79.7% of moxifloxacin patients achieved ECR (treatment difference, -0.46; 95% confidence interval [CI], -6.1 to 5.2). In the micro-ITT population, 80.3% of solithromycin patients and 79.1% of moxifloxacin patients achieved ECR (treatment difference, 1.26; 95% CI, -8.1 to 10.6). In the ITT population, 84.6% of solithromycin patients and 88.6% of moxifloxacin patients achieved clinical success at SFU based on investigator assessment. Mostly mild/moderate infusion events led to higher incidence of adverse events overall in the solithromycin group. Other adverse events were comparable between treatment groups. CONCLUSIONS: Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin. Solithromycin has potential to provide an intravenous and oral option for monotherapy for community-acquired bacterial pneumonia. CLINICAL TRIALS REGISTRATION: NCT01968733.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1093/cid/ciw490" target="_blank" rel="noreferrer noopener">10.1093/cid/ciw490</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*clinical trial
*Community-acquired
*Pneumonia
*solithromycin
*Streptococcus pneumoniae
2016
80 and over
Administration
Adult
Aged
Anti-Bacterial Agents/*administration & dosage/adverse effects
Bacterial
Bacterial/diagnosis/*drug therapy/*microbiology
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Community-Acquired Infections/diagnosis/*drug therapy/*microbiology
Comorbidity
Das Anita F
Department of Internal Medicine
Drug Resistance
Female
Fernandes Prabhavathi
File Thomas M Jr
Fluoroquinolones/*administration & dosage/adverse effects
Gonong Joven Roque V
Humans
Intravenous
Jamieson Brian D
Keedy Kara
Macrolides/*administration & dosage/adverse effects
Male
Microbial Sensitivity Tests
Middle Aged
Moxifloxacin
NEOMED College of Medicine
Oldach David
Oral
Pneumonia
Rewerska Barbara
Sheets Amanda
Taylor David
Treatment Outcome
Triazoles/*administration & dosage/adverse effects
Vucinic-Mihailovic Violeta
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1532/HSF98.20121103" target="_blank" rel="noreferrer noopener">http://doi.org/10.1532/HSF98.20121103</a>
Pages
E60–69
Issue
2
Volume
16
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
Publisher
An entity responsible for making the resource available
The heart surgery forum
Date
A point or period of time associated with an event in the lifecycle of the resource
2013
2013-04
Subject
The topic of the resource
Adult; Female; Humans; Male; Middle Aged; Aged; Treatment Outcome; Prevalence; United States/epidemiology; Risk Assessment; Adenosine Monophosphate/administration & dosage/*analogs & derivatives; Blood Transfusion/*statistics & numerical data; Coronary Artery Bypass/*statistics & numerical data; Drug-Related Side Effects and Adverse Reactions/epidemiology; Placebo Effect; Platelet Aggregation Inhibitors/administration & dosage; Postoperative Hemorrhage/*epidemiology/*prevention & control; Premedication/*statistics & numerical data; Purinergic P2Y Receptor Antagonists/administration & dosage; Pyridines/*administration & dosage; Injections; 80 and over; Intravenous; Administration; Drug Therapy; Oral; Combination/statistics & numerical data
Creator
An entity primarily responsible for making the resource
Firstenberg Michael S; Dyke Cornelius M; Angiolillo Dominick J; Ramaiahm Chandrashekar; Price Matthew; Brtko Miroslav; Welsby Ian; Chandna Harish; Holmes David R; Voeltz Michele; Tummala Pradyumna; Hutyra Martin; Manoukian Steven V; Prats Jayne; Todd Meredith; Liu Tiepu; Chronos Nicholas; Dietrich Markus; Montalescot Gilles; Cannon Louis A; Topo Eric J
Description
An account of the resource
OBJECTIVE: Oral P2Y(1)(2) platelet receptor inhibitors are a cornerstone of reducing complications in patients with acute coronary syndromes or coronary stents. Guidelines advocate discontinuing treatment with P2Y(1)(2) platelet receptor inhibitors before surgery. Cangrelor, a short-acting, reversible, intravenously administered P2Y(1)(2) platelet inhibitor is effective in achieving appropriate platelet inhibition in patients who are awaiting coronary artery bypass grafting (CABG) and require P2Y(1)(2) inhibition. The objective of this study was to assess the effects of preoperative cangrelor on the incidence of perioperative complications, which are currently unknown. METHODS: Patients (n = 210) requiring preoperative clinical administration of thienopyridine therapy were randomized in a multicenter, double-blinded study to receive cangrelor or placebo while awaiting CABG after discontinuation of the thienopyridine. Optimal platelet reactivity, which was defined as \textless240 P2Y(1)(2) platelet reaction units, was measured with serial point-of-care testing (VerifyNow). Pre- and postoperative outcomes, bleeding values, and transfusion rates were compared. To quantify potential risk factors for bleeding, we developed a multivariate logistic model. RESULTS: The differences between the groups in bleeding and perioperative transfusion rates were not significantly different. The rate of
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1532/HSF98.20121103" target="_blank" rel="noreferrer noopener">10.1532/HSF98.20121103</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2013
80 and over
Adenosine Monophosphate/administration & dosage/*analogs & derivatives
Administration
Adult
Aged
Angiolillo Dominick J
Blood Transfusion/*statistics & numerical data
Brtko Miroslav
Cannon Louis A
Chandna Harish
Chronos Nicholas
Combination/statistics & numerical data
Coronary Artery Bypass/*statistics & numerical data
Dietrich Markus
Drug Therapy
Drug-Related Side Effects and Adverse Reactions/epidemiology
Dyke Cornelius M
Female
Firstenberg Michael S
Holmes David R
Humans
Hutyra Martin
Injections
Intravenous
Liu Tiepu
Male
Manoukian Steven V
Middle Aged
Montalescot Gilles
Oral
Placebo Effect
Platelet Aggregation Inhibitors/administration & dosage
Postoperative Hemorrhage/*epidemiology/*prevention & control
Prats Jayne
Premedication/*statistics & numerical data
Prevalence
Price Matthew
Purinergic P2Y Receptor Antagonists/administration & dosage
Pyridines/*administration & dosage
Ramaiahm Chandrashekar
Risk Assessment
The heart surgery forum
Todd Meredith
Topo Eric J
Treatment Outcome
Tummala Pradyumna
United States/epidemiology
Voeltz Michele
Welsby Ian
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0272-6386(98)70042-3" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0272-6386(98)70042-3</a>
Pages
E4–E4
Issue
4
Volume
32
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Cyclosporine disposition and long-term renal function in a 500-pound kidney transplant recipient.
Publisher
An entity responsible for making the resource available
American journal of kidney diseases : the official journal of the National Kidney Foundation
Date
A point or period of time associated with an event in the lifecycle of the resource
1998
1998-10
Subject
The topic of the resource
Biological Availability; Cadaver; Chronic/surgery; Cyclosporine/administration & dosage/*pharmacokinetics; Diabetes Mellitus; Diabetic Nephropathies/surgery; Humans; Immunosuppressive Agents/administration & dosage/*pharmacokinetics; Injections; Intravenous; Kidney Failure; Kidney Function Tests; Kidney Transplantation/*physiology; Male; Middle Aged; Morbid/etiology/*physiopathology; Obesity; Type 1/complications
Creator
An entity primarily responsible for making the resource
Flechner S M; Haug M; Fisher R K; Modlin C S
Description
An account of the resource
Patient size has been suggested as a risk factor in kidney transplantation. We have followed a recipient of a cadaver kidney who became massively obese (232 kg, 511 lbs) 5 years posttransplantation. He has maintained stable renal function with no rejection episodes and at 5 years has a measured serum creatinine of 2.2 mg/dL, creatinine clearance 42 mL/min, and urinary protein excretion of 320 mg/24h. Both oral and intravenous cyclosporine (Sandimmune) pharmacokinetic studies were done on a steady-state dose of 150 mg, which represents 0.65 mg/kg per dose. The patient exhibited very high bioavailability, F = 95%, and an oral elimination T1/2 of over 21 hours. These data confirm that stable cyclosporine delivery in very obese recipients can be sustained by dosing normalized to the ideal body weight and trough level monitoring.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0272-6386(98)70042-3" target="_blank" rel="noreferrer noopener">10.1016/s0272-6386(98)70042-3</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1998
American journal of kidney diseases : the official journal of the National Kidney Foundation
Biological Availability
Cadaver
Chronic/surgery
Cyclosporine/administration & dosage/*pharmacokinetics
Diabetes Mellitus
Diabetic Nephropathies/surgery
Fisher R K
Flechner S M
Haug M
Humans
Immunosuppressive Agents/administration & dosage/*pharmacokinetics
Injections
Intravenous
Kidney Failure
Kidney Function Tests
Kidney Transplantation/*physiology
Male
Middle Aged
Modlin C S
Morbid/etiology/*physiopathology
Obesity
Type 1/complications
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
277–279
Issue
2
Volume
90
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Randomized comparison of gastric pH control with intermittent and continuous intravenous infusion of famotidine in ICU patients.
Publisher
An entity responsible for making the resource available
The American journal of gastroenterology
Date
A point or period of time associated with an event in the lifecycle of the resource
1995
1995-02
Subject
The topic of the resource
Female; Humans; Male; Middle Aged; Aged; Treatment Outcome; Prospective Studies; Analysis of Variance; Double-Blind Method; Hydrogen-Ion Concentration; Intensive Care Units; Drug Administration Schedule; Famotidine/administration & dosage/*therapeutic use; Stomach Ulcer/blood/etiology/*prevention & control; Stomach/*drug effects/physiopathology; Infusions; Intravenous
Creator
An entity primarily responsible for making the resource
Heiselman D E; Hulisz D T; Fricker R; Bredle D L; Black L D
Description
An account of the resource
OBJECTIVE: To compare gastric pH control using intravenous famotidine as a primed, continuous infusion versus intermittent infusion. METHODS: In a prospective, double-blind study, 40 ICU patients at risk for stress ulceration were randomly assigned to receive either famotidine 20 mg intravenous bolus followed by 1.67 mg/h infusion or famotidine 20 mg intravenously every 12 h. Intraluminal gastric pH was recorded at baseline and every 4 h using a glass electrode. Clinical outcome indicators were also monitored. Subjects were studied for a minimum of 24 h and a maximum of 6 days. Continuous variables were analyzed by ANOVA and nominal variables by Fisher's exact test (alpha = 0.05). RESULTS: Nineteen patients were randomized to the continuous infusion group, and 21 were randomized to the intermittent group. Using gastric pH greater than 4.0 as an endpoint, the continuous group exhibited better pH control, both in terms of percentage of total measurements (83% versus 63%, p \textless 0.001) and time spent above pH 4.0 (91% versus 76%, p \textless 0.01). Similar results were found at pH greater than 5.0 (78% versus 56% for all measurements for the continuous and bolus groups, respectively (p \textless 0.001), and 88% versus 72% for the time spent above pH 5.0 (p \textless 0.01). Clinical outcomes, including evidence for gastrointestinal bleeding and hospital mortality, did not differ significantly between groups. CONCLUSION: Famotidine infusion at 1.67 mg/h, when preceded by a bolus dose of 20 mg, provides a greater and more sustained increase in gastric pH than intermittent administration of famotidine 20 mg every 12 h.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1995
Aged
Analysis of Variance
Black L D
Bredle D L
Department of Internal Medicine
Double-Blind Method
Drug Administration Schedule
Famotidine/administration & dosage/*therapeutic use
Female
Fricker R
Heiselman D E
Hulisz D T
Humans
Hydrogen-Ion Concentration
Infusions
Intensive Care Units
Intravenous
Male
Middle Aged
NEOMED College of Medicine
Prospective Studies
Stomach Ulcer/blood/etiology/*prevention & control
Stomach/*drug effects/physiopathology
The American journal of gastroenterology
Treatment Outcome
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
174–180
Issue
2
Volume
84
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Early Uncomplicated Appendicitis-Who Can We Treat Nonoperatively?
Publisher
An entity responsible for making the resource available
American Surgeon
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
2018-02
Subject
The topic of the resource
Adult; Female; Male; Aged; Young Adult; Prospective Studies; Patient Selection; Drug Administration Schedule; Appendectomy; Injections; Human; Middle Age; Adolescence; Retrospective Design; Intravenous; Administration; Oral; Treatment Outcomes; Severity of Illness Indices; Antibiotics – Therapeutic Use; Ampicillin – Therapeutic Use; Appendicitis – Diagnosis; Appendicitis – Drug Therapy; Appendicitis – Surgery; Enzyme Inhibitors – Therapeutic Use; Penicillins – Therapeutic Use
Creator
An entity primarily responsible for making the resource
Horattas Mark C; HORATTAS ILEANA K; VASILIOU ELYA M
Description
An account of the resource
This study evaluated nonoperative treatment for mild appendicitis and reviewed selection criteria to be used in introducing this option into clinical practice. A retrospective review of 73 consecutive cases of appendicitis treated by a single surgeon from 2011 to 2013 was completed. Patients who were diagnosed with mild appendicitis meeting the criteria of an APPENDICITIS scoring algorithm proposed in this manuscript were considered for nonoperative management. An additional 17 patients with mild appendicitis were offered and successfully treated nonoperatively between 2014 and 2016 and reviewed. Of these original 73 patients, 37 had moderate to severe appendicitis and directly underwent appendectomy. The remaining patients were diagnosed with mild appendicitis and considered eligible for nonoperative management. Of these, 14 patients were offered nonoperative therapy. Thirteen responded successfully; one patient responded partially, but later opted for surgery. In 2014, this scoring system and preliminary results were shared with the other surgeons in our department. Nonoperative management was then selectively adopted by a few of the surgeons from 2014 to 2016 with another 17 patients (APPENDICITIS score of 0 or 1) being offered and successfully managed nonoperatively. Patients with mild or early appendicitis can be successfully managed nonoperatively. A proposed APPENDICITIS scoring system may provide a helpful mnemonic for successfully selecting patients for this option.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Administration
Adolescence
Adult
Aged
American Surgeon
Ampicillin – Therapeutic Use
Antibiotics – Therapeutic Use
Appendectomy
Appendicitis – Diagnosis
Appendicitis – Drug Therapy
Appendicitis – Surgery
Drug Administration Schedule
Enzyme Inhibitors – Therapeutic Use
Female
HORATTAS ILEANA K
Horattas Mark C
Human
Injections
Intravenous
Male
Middle Age
Oral
Patient Selection
Penicillins – Therapeutic Use
Prospective Studies
Retrospective Design
Severity of Illness Indices
Treatment Outcomes
VASILIOU ELYA M
Young Adult
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.yjmcc.2015.09.001" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.yjmcc.2015.09.001</a>
Pages
14–28
Volume
88
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Overexpressing superoxide dismutase 2 induces a supernormal cardiac function by enhancing redox-dependent mitochondrial function and metabolic dilation.
Publisher
An entity responsible for making the resource available
Journal of molecular and cellular cardiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-11
Subject
The topic of the resource
Adenosine Triphosphate/biosynthesis; Animals; Arterial Pressure/drug effects; Bioenergetics; Blood Flow Velocity/drug effects; Cardiac function; Cardiac/drug effects/*enzymology; Catalase/pharmacology; Echocardiography; Female; Gene Expression; Heart/drug effects/*enzymology; Hydrogen Peroxide/*metabolism/pharmacology; Injections; Intravenous; Male; Metabolic dilation; Mice; Mitochondria; Myocardium/*enzymology; Myocytes; NG-Nitroarginine Methyl Ester/pharmacology; Oxidation-Reduction; Oxygen Consumption/drug effects; Redox regulation; Signal Transduction; Stroke Volume/drug effects; Superoxide dismutase 2 (SOD2); Superoxide Dismutase/*genetics/metabolism; Transgenic; Transgenic mice; Vasodilation/*drug effects
Creator
An entity primarily responsible for making the resource
Kang Patrick T; Chen Chwen-Lih; Ohanyan Vahagn; Luther Daniel J; Meszaros J Gary; Chilian William M; Chen Yeong-Renn
Description
An account of the resource
During heightened cardiac work, O2 consumption by the heart benefits energy production via mitochondria. However, some electrons leak from the respiratory chain and yield superoxide, which is rapidly metabolized into H2O2 by SOD2. To understand the systemic effects of the metabolic dilator, H2O2, we studied mice with cardiac-specific SOD2 overexpression (SOD2-tg), which increases the H2O2 produced by cardiac mitochondria. Contrast echocardiography was employed to evaluate cardiac function, indicating that SOD2-tg had a significantly greater ejection fraction and a lower mean arterial pressure (MAP) that was partially normalized by intravenous injection of catalase. Norepinephrine-mediated myocardial blood flow (MBF) was significantly enhanced in SOD2-tg mice. Coupling of MBF to the double product (Heart RatexMAP) was increased in SOD2-tg mice, indicating that the metabolic dilator, "spilled" over, inducing systemic vasodilation. The hypothesis that SOD2 overexpression effectively enhances mitochondrial function was further evaluated. Mitochondria of SOD2-tg mice had a decreased state 3 oxygen consumption rate, but maintained the same ATP production flux under the basal and L-NAME treatment conditions, indicating a higher bioenergetic efficiency. SOD2-tg mitochondria produced less superoxide, and had lower redox activity in converting cyclic hydroxylamine to stable nitroxide, and a lower GSSG concentration. EPR analysis of the isolated mitochondria showed a significant decrease in semiquinones at the SOD2-tg Qi site. These results support a more reductive physiological setting in the SOD2-tg murine heart. Cardiac mitochondria exhibited no significant differences in the respiratory control index between WT and SOD2-tg. We conclude that SOD2 overexpression in myocytes enhances mitochondrial function and metabolic vasodilation, leading to a phenotype of supernormal cardiac function.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.yjmcc.2015.09.001" target="_blank" rel="noreferrer noopener">10.1016/j.yjmcc.2015.09.001</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Adenosine Triphosphate/biosynthesis
Animals
Arterial Pressure/drug effects
Bioenergetics
Blood Flow Velocity/drug effects
Cardiac function
Cardiac/drug effects/*enzymology
Catalase/pharmacology
Chen Chwen-Lih
Chen Yeong-Renn
Chilian William M
Department of Integrative Medical Sciences
Echocardiography
Female
Gene Expression
Heart/drug effects/*enzymology
Hydrogen Peroxide/*metabolism/pharmacology
Injections
Intravenous
Journal of molecular and cellular cardiology
Kang Patrick T
Luther Daniel J
Male
Meszaros J Gary
Metabolic dilation
Mice
Mitochondria
Myocardium/*enzymology
Myocytes
NEOMED College of Medicine
NG-Nitroarginine Methyl Ester/pharmacology
Ohanyan Vahagn
Oxidation-Reduction
Oxygen Consumption/drug effects
Redox regulation
Signal Transduction
Stroke Volume/drug effects
Superoxide dismutase 2 (SOD2)
Superoxide Dismutase/*genetics/metabolism
Transgenic
Transgenic mice
Vasodilation/*drug effects
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.066" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.066</a>
Pages
e48–e49
Issue
3
Volume
27
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Safe Readministration of Intravenous Thrombolysis in Recurrent Basilar Thrombosis.
Publisher
An entity responsible for making the resource available
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
2018-03
Subject
The topic of the resource
Aged; Basilar Artery; Basilar Artery – Drug Effects; Basilar Artery – Physiopathology; Basilar Artery/diagnostic imaging/*drug effects/physiopathology; Cerebral Angiography – Methods; Cerebral Angiography/methods; Computed Tomography Angiography; Drug Administration Schedule; Fibrinolytic Agents – Administration and Dosage; Fibrinolytic Agents – Adverse Effects; Fibrinolytic Agents/*administration & dosage/adverse effects; Humans; Infusions; Intracranial Thrombosis; Intracranial Thrombosis – Drug Therapy; Intracranial Thrombosis – Physiopathology; Intracranial Thrombosis/diagnostic imaging/*drug therapy/physiopathology; Intravenous; Magnetic Resonance Imaging; Male; medication safety; Recombinant Proteins – Administration and Dosage; Recombinant Proteins/administration & dosage; Recurrence; recurrent stroke; Repeat Procedures; Retreatment; thrombolysis; Thrombolytic Therapy – Adverse Effects; Thrombolytic Therapy – Methods; Thrombolytic Therapy/adverse effects/*methods; Thrombosis; Time Factors; Tissue Plasminogen Activator – Administration and Dosage; Tissue Plasminogen Activator – Adverse Effects; Tissue Plasminogen Activator/*administration & dosage/adverse effects; Treatment Outcome; Treatment Outcomes
Creator
An entity primarily responsible for making the resource
Khan Alina; Itrat Ahmed
Description
An account of the resource
We report a patient who had recurrence of stroke in the basilar artery territory because of repeat thrombosis, and was administered intravenous recombinant tissue plasminogen activator (IV-rtPA) twice within a span of 3 weeks without any adverse events, with radiological evidence of successful thrombolysis. Because of minor and improving stroke symptoms with IV-rtPA, endovascular therapy was not performed and there was radiological evidence of recanalization with IV-rtPA alone. This report adds to the very limited literature on the topic demonstrating safe and successful use of repeat IV thrombolysis following a previous recent stroke.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jstrokecerebrovasdis.2017.09.066" target="_blank" rel="noreferrer noopener">10.1016/j.jstrokecerebrovasdis.2017.09.066</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Aged
Basilar Artery
Basilar Artery – Drug Effects
Basilar Artery – Physiopathology
Basilar Artery/diagnostic imaging/*drug effects/physiopathology
Cerebral Angiography – Methods
Cerebral Angiography/methods
Computed Tomography Angiography
Department of Internal Medicine
Drug Administration Schedule
Fibrinolytic Agents – Administration and Dosage
Fibrinolytic Agents – Adverse Effects
Fibrinolytic Agents/*administration & dosage/adverse effects
Humans
Infusions
Intracranial Thrombosis
Intracranial Thrombosis – Drug Therapy
Intracranial Thrombosis – Physiopathology
Intracranial Thrombosis/diagnostic imaging/*drug therapy/physiopathology
Intravenous
Itrat Ahmed
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
Khan Alina
Magnetic Resonance Imaging
Male
medication safety
NEOMED College of Medicine
Recombinant Proteins – Administration and Dosage
Recombinant Proteins/administration & dosage
Recurrence
recurrent stroke
Repeat Procedures
Retreatment
thrombolysis
Thrombolytic Therapy – Adverse Effects
Thrombolytic Therapy – Methods
Thrombolytic Therapy/adverse effects/*methods
Thrombosis
Time Factors
Tissue Plasminogen Activator – Administration and Dosage
Tissue Plasminogen Activator – Adverse Effects
Tissue Plasminogen Activator/*administration & dosage/adverse effects
Treatment Outcome
Treatment Outcomes
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0002-9629(15)40823-7" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0002-9629(15)40823-7</a>
Pages
214–218
Issue
3
Volume
320
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
A subtherapeutic international normalized ratio despite increasing doses of warfarin: could this be malabsorption?
Publisher
An entity responsible for making the resource available
The American journal of the medical sciences
Date
A point or period of time associated with an event in the lifecycle of the resource
2000
2000-09
Subject
The topic of the resource
*Drug Resistance; Administration; Adult; Anticoagulants/administration & dosage/metabolism/pharmacokinetics/therapeutic use; Area Under Curve; Biological Availability; Dose-Response Relationship; Drug; Female; Humans; Injections; Intestinal Absorption/*physiology; Intravenous; Kidney Transplantation; Oral; Warfarin/*administration & dosage/*metabolism/pharmacokinetics/therapeutic use
Creator
An entity primarily responsible for making the resource
Lara L F; Delgado L L; Frazee L A; Haupt K M; Rutecki G W
Description
An account of the resource
OBJECTIVE: To describe a case of warfarin resistance apparently caused by malabsorption and to review the literature regarding warfarin resistance. CASE SUMMARY: A 28-year-old renal transplant patient with systemic lupus erythematosus was admitted for upper extremity thrombophlebitis. Resistance to oral warfarin was demonstrated. Potential causes were investigated. The trapezoidal rule was used to compare the area under the curve for intravenous versus oral dosing of warfarin. The usual bioavailability of warfarin should be 100%. In this patient, warfarin bioavailability after oral dosing was 1.5%. Three potential causes, malabsorption (FF), enzymatic degradation (FG), and first-pass extraction in the portal circulation (FH), are discussed. CONCLUSION: This case demonstrates resistance to warfarin presumably caused by malabsorption.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0002-9629(15)40823-7" target="_blank" rel="noreferrer noopener">10.1016/s0002-9629(15)40823-7</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Drug Resistance
2000
Administration
Adult
Anticoagulants/administration & dosage/metabolism/pharmacokinetics/therapeutic use
Area Under Curve
Biological Availability
Delgado L L
Department of Family & Community Medicine
Department of Internal Medicine
Dose-Response Relationship
Drug
Female
Frazee L A
Haupt K M
Humans
Injections
Intestinal Absorption/*physiology
Intravenous
Kidney Transplantation
Lara L F
NEOMED College of Medicine
Oral
Rutecki G W
The American journal of the medical sciences
Warfarin/*administration & dosage/*metabolism/pharmacokinetics/therapeutic use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0002-9610(99)00153-1" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0002-9610(99)00153-1</a>
Pages
121–124
Issue
2
Volume
178
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Awake aortic aneurysm repair in patients with severe pulmonary disease.
Publisher
An entity responsible for making the resource available
American journal of surgery
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
1999-08
Subject
The topic of the resource
*Consciousness; Abdominal/*surgery; Administration; Aged; Albuterol/administration & dosage/therapeutic use; Anesthesia; Aortic Aneurysm; Blood Loss; Bronchodilator Agents/administration & dosage/therapeutic use; Critical Care; Epidural; Forced Expiratory Volume/physiology; General; Home Care Services; Hospitalization; Humans; Hypnotics and Sedatives/administration & dosage; Iliac Aneurysm/*surgery; Inhalation; Intravenous; Length of Stay; Lung Diseases/*complications/drug therapy/therapy; Oxygen Inhalation Therapy; Retroperitoneal Space; Retrospective Studies; Risk Factors; Safety; Steroids/administration & dosage/therapeutic use; Surgical; Theophylline/administration & dosage/therapeutic use; Time Factors; Vital Capacity/physiology
Creator
An entity primarily responsible for making the resource
McGregor W E; Koler A J; Labat G C; Perni V; Hirko M K; Rubin J R
Description
An account of the resource
BACKGROUND: We report the use of retroperitoneal aortic aneurysm repair utilizing exclusive regional anesthesia (no intubation or inhalation anesthetic) in high pulmonary risk patients. METHODS: Six patients were retrospectively reviewed. Pulmonary disease was diagnosed by clinical history and pulmonary function tests. Patients received intravenous sedation and regional anesthesia. Retroperitoneal aortoiliac aneurysm repair was performed. RESULTS: All patients used inhaled steroids and albuterol. Three required theophylline and home oxygen. FEV1 = 23% +/- 5% predicted, FVC = 34% +/- 5% predicted, and PO2 = 62 +/- 2 mm Hg. Operative time was 247 +/- 25 minutes. Blood loss was 840 +/- 479 mL. Five of six patients (83%) tolerated awake aneurysm repair and had intensive care unit stays of 2.4 +/- 0.6 days, and postoperative hospital stays of 8.2 +/- 1.8 days. One patient was converted to general anesthesia and had a prolonged hospital stay. CONCLUSIONS: With thorough patient communication, awake retroperitoneal aortic aneurysm repair can be safely performed in select patients with severe pulmonary disease.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0002-9610(99)00153-1" target="_blank" rel="noreferrer noopener">10.1016/s0002-9610(99)00153-1</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Consciousness
1999
Abdominal/*surgery
Administration
Aged
Albuterol/administration & dosage/therapeutic use
American journal of surgery
Anesthesia
Aortic Aneurysm
Blood Loss
Bronchodilator Agents/administration & dosage/therapeutic use
Critical Care
Epidural
Forced Expiratory Volume/physiology
General
Hirko M K
Home Care Services
Hospitalization
Humans
Hypnotics and Sedatives/administration & dosage
Iliac Aneurysm/*surgery
Inhalation
Intravenous
Koler A J
Labat G C
Length of Stay
Lung Diseases/*complications/drug therapy/therapy
McGregor W E
Oxygen Inhalation Therapy
Perni V
Retroperitoneal Space
Retrospective Studies
Risk Factors
Rubin J R
Safety
Steroids/administration & dosage/therapeutic use
Surgical
Theophylline/administration & dosage/therapeutic use
Time Factors
Vital Capacity/physiology
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1152/ajpheart.00082.2011" target="_blank" rel="noreferrer noopener">http://doi.org/10.1152/ajpheart.00082.2011</a>
Pages
H1135–1142
Issue
3
Volume
301
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Endothelin-mediated in vivo pressor responses following TRPV1 activation.
Publisher
An entity responsible for making the resource available
American journal of physiology. Heart and circulatory physiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2011
2011-09
Subject
The topic of the resource
*Blood Pressure/drug effects; *Vasoconstriction/drug effects; Adrenergic alpha-Agonists/administration & dosage; Analysis of Variance; Animal; Animals; Azepines/administration & dosage; Biphenyl Compounds/administration & dosage; Capsaicin/administration & dosage; Cells; Cultured; Diabetes Mellitus; Diabetic Angiopathies/genetics/*metabolism/physiopathology; Dipeptides/administration & dosage; Disease Models; Dose-Response Relationship; Drug; Endothelial Cells/metabolism; Endothelin A Receptor Antagonists; Endothelin A/metabolism; Endothelin B Receptor Antagonists; Endothelin B/metabolism; Endothelin-1/*metabolism; Enzyme-Linked Immunosorbent Assay; Femoral Artery/drug effects/*metabolism/physiopathology; Inbred C57BL; Indoles/administration & dosage; Infusions; Intravenous; Knockout; Male; Mice; Phenylephrine/administration & dosage; Receptor; TRPV Cation Channels/agonists/deficiency/genetics/*metabolism; Type 2/genetics/*metabolism/physiopathology; Vasoconstrictor Agents/administration & dosage
Creator
An entity primarily responsible for making the resource
Ohanyan Vahagn A; Guarini Giacinta; Thodeti Charles K; Talasila Phani K; Raman Priya; Haney Rebecca M; Meszaros J Gary; Damron Derek S; Bratz Ian N
Description
An account of the resource
Transient receptor potential vanilliod 1 (TRPV1) channels have recently been postulated to play a role in the vascular complications/consequences associated with diabetes despite the fact that the mechanisms through which TRPV1 regulates vascular function are not fully known. Accordingly, our goal was to define the mechanisms by which TRPV1 channels modulate vascular function and contribute to vascular dysfunction in diabetes. We subjected mice lacking TRPV1 [TRPV1((-/-))], db/db, and control C57BLKS/J mice to in vivo infusion of the TRPV1 agonist capsaicin or the alpha-adrenergic agonist phenylephrine (PE) to examine the integrated circulatory actions of TRPV1. Capsaicin (1, 10, 20, and 100 mug/kg) dose dependently increased MAP in control mice (5.7 +/- 1.6, 11.7 +/- 2.1, 25.4 +/- 3.4, and 51.6 +/- 3.9%), which was attenuated in db/db mice (3.4 +/- 2.1, 3.9 +/- 2.1, 7.0 +/- 3.3, and 17.9 +/- 6.2%). TRPV1((-/-)) mice exhibited no changes in MAP in response to capsaicin, suggesting the actions of this agonist are specific to TRPV1 activation. Immunoblot analysis revealed decreased aortic TRPV1 protein expression in db/db compared with control mice. Capsaicin-induced responses were recorded following inhibition of endothelin A and B receptors (ET(A) /ET(B)). Inhibition of ET(A) receptors abolished the capsaicin-mediated increases in MAP. Combined antagonism of ET(A) and ET(B) receptors did not further inhibit the capsaicin response. Cultured endothelial cell exposure to capsaicin increased endothelin production as shown by an endothelin ELISA assay, which was attenuated by inhibition of TRPV1 or endothelin-converting enzyme. TRPV1 channels contribute to the regulation of vascular reactivity and MAP via production of endothelin and subsequent activation of vascular ET(A) receptors. Impairment of TRPV1 channel function may contribute to vascular dysfunction in diabetes.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1152/ajpheart.00082.2011" target="_blank" rel="noreferrer noopener">10.1152/ajpheart.00082.2011</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Blood Pressure/drug effects
*Vasoconstriction/drug effects
2011
Adrenergic alpha-Agonists/administration & dosage
American journal of physiology. Heart and circulatory physiology
Analysis of Variance
Animal
Animals
Azepines/administration & dosage
Biphenyl Compounds/administration & dosage
Bratz Ian N
Capsaicin/administration & dosage
Cells
Cultured
Damron Derek S
Department of Integrative Medical Sciences
Diabetes Mellitus
Diabetic Angiopathies/genetics/*metabolism/physiopathology
Dipeptides/administration & dosage
Disease Models
Dose-Response Relationship
Drug
Endothelial Cells/metabolism
Endothelin A Receptor Antagonists
Endothelin A/metabolism
Endothelin B Receptor Antagonists
Endothelin B/metabolism
Endothelin-1/*metabolism
Enzyme-Linked Immunosorbent Assay
Femoral Artery/drug effects/*metabolism/physiopathology
Guarini Giacinta
Haney Rebecca M
Inbred C57BL
Indoles/administration & dosage
Infusions
Intravenous
Knockout
Male
Meszaros J Gary
Mice
NEOMED College of Medicine
Ohanyan Vahagn A
Phenylephrine/administration & dosage
Raman Priya
Receptor
Talasila Phani K
Thodeti Charles K
TRPV Cation Channels/agonists/deficiency/genetics/*metabolism
Type 2/genetics/*metabolism/physiopathology
Vasoconstrictor Agents/administration & dosage
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/j.jns.2015.04.042" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/j.jns.2015.04.042</a>
Pages
37–45
Issue
1
Volume
354
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Anti-edema action of thyroid hormone in MCAO model of ischemic brain stroke: Possible association with AQP4 modulation.
Publisher
An entity responsible for making the resource available
Journal of the neurological sciences
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-07
Subject
The topic of the resource
Animals; Aquaporin 4/*physiology; Aquaporin-4; Brain Edema/*drug therapy/pathology; Cerebral edema; Cerebrovascular Circulation/drug effects/physiology; Diiodothyronines/*administration & dosage; Erythropoietin; Infarction; Injections; Intravenous; Ischemic brain stroke; Male; Mice; Middle cerebral artery occlusion (MCAO); Middle Cerebral Artery/*drug therapy/pathology; Stroke/*drug therapy/pathology; Thyroid hormone; Triiodothyronine/*administration & dosage
Creator
An entity primarily responsible for making the resource
Sadana Prabodh; Coughlin Lucy; Burke Jamie; Woods Robert; Mdzinarishvili Alexander
Description
An account of the resource
The use of neuroprotective strategies to mitigate the fatal consequences of ischemic brain stroke is a focus of robust research activity. We have previously demonstrated that thyroid hormone (T3; 3,3',5-triiodo-l-thyronine) possesses neuroprotective and anti-edema activity in pre-stroke treatment regimens when administered as a solution or as a nanoparticle formulation. In this study we have extended our evaluation of thyroid hormone use in animal models of brain stroke. We have used both transient middle cerebral artery occlusion (t-MCAO) and permanent (p-MCAO) models of ischemic brain stroke. A significant reduction of tissue infarction and a concurrent decrease in edema were observed in the t-MCAO model of brain stroke. However, no benefit of T3 was observed in p-MCAO stroke setting. Significant improvement of neurological outcomes was observed upon T3 treatment in t-MCAO mice. Further, we tested T2 (3,5-diiodo-l-thyronine) a natural deiodination metabolite of T3 in MCAO model of brain stroke. T2 potently decreased infarct size as well as edema formation. Additionally, we report here that T3 suppresses the expression of aquaporin-4 (AQP4) water channels which could be a likely mechanism of its anti-edema activity. Our studies provide evidence to stimulate clinical development of thyroid hormones for use in ischemic brain stroke.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/j.jns.2015.04.042" target="_blank" rel="noreferrer noopener">10.1016/j.jns.2015.04.042</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Animals
Aquaporin 4/*physiology
Aquaporin-4
Brain Edema/*drug therapy/pathology
Burke Jamie
Cerebral edema
Cerebrovascular Circulation/drug effects/physiology
Coughlin Lucy
Department of Pharmaceutical Sciences
Department of Pharmacy Practice
Diiodothyronines/*administration & dosage
Erythropoietin
Infarction
Injections
Intravenous
Ischemic brain stroke
Journal of the neurological sciences
Male
Mdzinarishvili Alexander
Mice
Middle cerebral artery occlusion (MCAO)
Middle Cerebral Artery/*drug therapy/pathology
NEOMED College of Graduate Studies
NEOMED College of Pharmacy
Sadana Prabodh
Stroke/*drug therapy/pathology
Thyroid hormone
Triiodothyronine/*administration & dosage
Woods Robert
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.5966/sctm.2013-0157" target="_blank" rel="noreferrer noopener">http://doi.org/10.5966/sctm.2013-0157</a>
Pages
760–767
Issue
6
Volume
3
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells.
Publisher
An entity responsible for making the resource available
Stem cells translational medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-06
Subject
The topic of the resource
Female; Time Factors; Animals; Rats; Mesenchymal stem cells; Transfection; Recovery of Function; Fibrosis; *Mesenchymal Stem Cell Transplantation; *Regeneration; Anal Canal/injuries/metabolism/pathology/physiopathology/*surgery; Anal pressures; Anal sphincter; Fecal incontinence; Green Fluorescent Proteins/biosynthesis/genetics; i.v. infusion; Mesenchymal Stem Cells/metabolism; Pressure; Injections; Intralesional; Sprague-Dawley; Cells; Cultured; Animal; Disease Models; Infusions; Intravenous
Creator
An entity primarily responsible for making the resource
Salcedo Levilester; Penn Marc; Damaser Margot; Balog Brian; Zutshi Massarat
Description
An account of the resource
This research demonstrates the regenerative effects of mesenchymal stem cells (MSCs) on the injured anal sphincter by comparing anal sphincter pressures following intramuscular and serial intravascular MSC infusion in a rat model of anal sphincter injury. Fifty rats were divided into injury (n = 35) and no injury (NI; n = 15) groups. Each group was further divided into i.m., serial i.v., or no-treatment (n = 5) groups and followed for 5 weeks. The injury consisted of an excision of 25% of the anal sphincter complex. Twenty-four hours after injury, 5 x 10(5) green fluorescent protein-labeled MSCs in 0.2 ml of phosphate-buffered saline (PBS) or PBS alone (sham) were injected into the anal sphincter for i.m. treatment; i.v. and sham i.v. treatments were delivered daily for 6 consecutive days via the tail vein. Anal pressures were recorded before injury and 10 days and 5 weeks after treatment. Ten days after i.m. MSC treatment, resting and peak pressures were significantly increased compared with those in sham i.m. treatment (p \textless .001). When compared with the NI group, the injury groups had anal pressures that were not significantly different 5 weeks after i.m./i.v. treatment. Both resting and peak pressures were also significantly increased after i.m./i.v. MSC treatment compared with treatment with PBS (p \textless .001), suggesting recovery. Statistical analysis was done using paired t test with Bonferroni correction. Marked decrease in fibrosis and scar tissue was seen in both MSC-treated groups. Both i.m. and i.v. MSC treatment after injury caused an increase in anal pressures sustained at 5 weeks, although fewer cells were injected i.m. The
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.5966/sctm.2013-0157" target="_blank" rel="noreferrer noopener">10.5966/sctm.2013-0157</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
*Mesenchymal Stem Cell Transplantation
*Regeneration
2014
Anal Canal/injuries/metabolism/pathology/physiopathology/*surgery
Anal pressures
Anal sphincter
Animal
Animals
Balog Brian
Cells
Cultured
Damaser Margot
Disease Models
Fecal incontinence
Female
Fibrosis
Green Fluorescent Proteins/biosynthesis/genetics
i.v. infusion
Infusions
Injections
Intralesional
Intravenous
Mesenchymal stem cells
Mesenchymal Stem Cells/metabolism
Penn Marc
Pressure
Rats
Recovery of Function
Salcedo Levilester
Sprague-Dawley
Stem cells translational medicine
Time Factors
Transfection
Zutshi Massarat
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1097/00003246-199306000-00025" target="_blank" rel="noreferrer noopener">http://doi.org/10.1097/00003246-199306000-00025</a>
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
938-940
Issue
6
Volume
21
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
CONTINUOUS-INFUSION OF PYRIDOSTIGMINE IN THE MANAGEMENT OF MYASTHENIC CRISIS
Publisher
An entity responsible for making the resource available
Critical Care Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
1993
1993-06
Subject
The topic of the resource
cholinergic; cholinesterase inhibitors; compounds; edrophonium; General & Internal Medicine; gravis; injections; intravenous; kinetics; myasthenia gravis; neostigmine; neuromuscular diseases; ocular motility disorders; pyridinium; pyridostigmine bromide; receptors; ventilatory weaning
Creator
An entity primarily responsible for making the resource
Saltis L M; Martin B R; Traeger S M; Bonfiglio M F
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1097/00003246-199306000-00025" target="_blank" rel="noreferrer noopener">10.1097/00003246-199306000-00025</a>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
1993
Bonfiglio M F
cholinergic
cholinesterase inhibitors
compounds
Critical care medicine
edrophonium
General & Internal Medicine
gravis
Injections
Intravenous
Journal Article
Kinetics
Martin B R
myasthenia gravis
neostigmine
neuromuscular diseases
ocular motility disorders
pyridinium
pyridostigmine bromide
Receptors
Saltis L M
Traeger S M
ventilatory weaning
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1128/aac.36.7.1400" target="_blank" rel="noreferrer noopener">http://doi.org/10.1128/aac.36.7.1400</a>
Pages
1400–1403
Issue
7
Volume
36
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration.
Publisher
An entity responsible for making the resource available
Antimicrobial agents and chemotherapy
Date
A point or period of time associated with an event in the lifecycle of the resource
1992
1992-07
Subject
The topic of the resource
Adult; Biological Availability; Cilastatin/administration & dosage/pharmacokinetics; Humans; Imipenem/administration & dosage/blood/*pharmacokinetics; Infusions; Injections; Intramuscular; Intravenous; Male; Middle Aged; Skin/*metabolism
Creator
An entity primarily responsible for making the resource
Signs S A; Tan J S; Salstrom S J; File T M
Description
An account of the resource
The pharmacokinetic profiles of imipenem after intramuscular (i.m.) and intravenous injections were examined in adult volunteers. Levels of imipenem in serum after i.m. injection of a microcrystalline suspension of imipenem-cilastatin (500 mg each) reached a peak (8.0 micrograms/ml) at 1.5 h after administration, and concentrations were maintained in excess of 1.5 micrograms/ml for 6 h. Serum elimination half-life (1.3 h), volume of distribution (14.5 liters), and area under the curve (AUC; 27.8 micrograms.h/ml) after i.m. injection did not significantly differ from those of a comparable dose given by intravenous infusion. Bioavailability after i.m. injection was 89%. Imipenem levels in skin window fluid after i.m. administration were maximal (4.3 micrograms/ml) at 4 h after injection, at which time imipenem concentrations exceeded those produced by intravenous infusion. The AUCskin window/AUCserum ratio for skin window fluid after i.m. injection was 68%, indicating good penetration of the drug into skin fluid. This study shows that i.m. injection of 500 mg of imipenem-cilastatin results in concentrations of imipenem in serum and skin fluid that are, for at least 6 h, consistent with antimicrobial activity against susceptible organisms.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1128/aac.36.7.1400" target="_blank" rel="noreferrer noopener">10.1128/aac.36.7.1400</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1992
Adult
Antimicrobial agents and chemotherapy
Biological Availability
Cilastatin/administration & dosage/pharmacokinetics
Department of Internal Medicine
File T M
Humans
Imipenem/administration & dosage/blood/*pharmacokinetics
Infusions
Injections
Intramuscular
Intravenous
Male
Middle Aged
NEOMED College of Medicine
Salstrom S J
Signs S A
Skin/*metabolism
Tan J S
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
n/a
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
3749-3752
Issue
9
Volume
32
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Pharmacokinetics of Intravenous Nitrosylcobalamin, an Antitumor Agent, in Healthy Beagle Dogs: A Pilot Study
Publisher
An entity responsible for making the resource available
Anticancer Research
Date
A point or period of time associated with an event in the lifecycle of the resource
2012
2012-09
Subject
The topic of the resource
apo2l/trail; canine organs; cobalamin; cobalamin vitamin-b-12; dogs; intravenous; nitric-oxide; Nitrosylcobalamin; Oncology; pharmacokinetics; protein; release; suppression; transcobalamin-ii; transport; vitamin B-12
Creator
An entity primarily responsible for making the resource
Sysel A M; Horne W I; Steiner J M; Suchodolski J S; Bauer J A
Description
An account of the resource
Background/Aim: Nitrosylcobalamin (NO-Cbl) is a cobalamin-based anti-tumor agent. This study evaluated the pharmacokinetic parameters of NO-Cbl following intravenous administration in dogs. Materials and Methods: Four dogs received 10 mg/kg, 20 mg/kg and 40 mg/kg intravenous bolus doses of NO-Cbl, with a 14-day washout period between doses. Blood samples were collected at baseline and post-dosing, and noncompartmental pharmacokinetic parameters were determined. Results: Average peak serum concentrations of 2265, 5523 and 13,866 pg/mL were achieved following single-dose bolus intravenous administration of 10 mg/kg, 20 mg/kg and 40 mg/kg of NO-Cbl respectively. The average area under the curve was 12,697 h x pg/mL, 24,497 h x pg/mL and 44,976 h x pg/mL respectively, with an average elimination half-life of 16.2 h, 13.5 h and 13.1 h respectively. Conclusion: These results can be used to determine the dose and dosing intervals for clinical trials evaluating NO-Cbl in humans and companion animals.
Identifier
An unambiguous reference to the resource within a given context
n/a
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2012
Anticancer research
apo2l/trail
Bauer J A
canine organs
cobalamin
cobalamin vitamin-b-12
Dogs
Horne W I
Intravenous
Journal Article
nitric-oxide
Nitrosylcobalamin
oncology
pharmacokinetics
Protein
release
Steiner J M
Suchodolski J S
suppression
Sysel A M
transcobalamin-ii
transport
vitamin B-12
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Pages
132–133
Issue
17
Volume
37
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Antibiotics for Acute Appendicitis.
Publisher
An entity responsible for making the resource available
Internal Medicine Alert
Date
A point or period of time associated with an event in the lifecycle of the resource
2015
2015-09-15
Subject
The topic of the resource
Postoperative Complications; Antibiotics; Length of Stay; Decision Making; Appendectomy; Tomography; Human; Multicenter Studies; X-Ray Computed; Intravenous; Administration; Treatment Outcomes; Patient Education; Randomized Controlled Trials; Emergency Treatment; Antibiotics – Therapeutic Use; Appendicitis – Ultrasonography; Appendicitis – Drug Therapy; Appendicitis – Surgery
Creator
An entity primarily responsible for making the resource
Watkins Richard R
Description
An account of the resource
The article reports that patients with uncomplicated acute appendicitis can fair well without surgery as compared to clinical trial patients who underwent surgery, and states that patients had lower risk of complications during the one-year follow-up period.
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2015
Administration
Antibiotics
Antibiotics – Therapeutic Use
Appendectomy
Appendicitis – Drug Therapy
Appendicitis – Surgery
Appendicitis – Ultrasonography
Decision Making
Department of Internal Medicine
Emergency Treatment
Human
Internal Medicine Alert
Intravenous
Length of Stay
Multicenter Studies
NEOMED College of Medicine
Patient Education
Postoperative Complications
RANDOMIZED controlled trials
Tomography
Treatment Outcomes
Watkins Richard R
X-Ray Computed
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1067/mem.2000.110823" target="_blank" rel="noreferrer noopener">http://doi.org/10.1067/mem.2000.110823</a>
Pages
427–431
Issue
5
Volume
36
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The bronchodilator effect of intravenous glucagon in asthma exacerbation: a randomized, controlled trial.
Publisher
An entity responsible for making the resource available
Annals of emergency medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2000
2000-11
Subject
The topic of the resource
Adult; Asthma/complications/*drug therapy; Bronchodilator Agents/*administration & dosage; Double-Blind Method; Female; Glucagon/*administration & dosage; Humans; Injections; Intravenous; Male
Creator
An entity primarily responsible for making the resource
Wilber S T; Wilson J E; Blanda M; Gerson L W; Meerbaum S O; Janas G
Description
An account of the resource
STUDY OBJECTIVE: Glucagon is a rapid-acting smooth muscle relaxant with a short half-life. Previous studies suggested glucagon may have bronchodilator effects. We sought to determine whether intravenous glucagon produces clinically important immediate bronchodilation in emergency department patients with asthma exacerbation. METHODS: We conducted a randomized, double-blind, placebo-controlled study at 2 university-affiliated community teaching hospital EDs (annual census 90,000). ED patients 18 to 50 years old with asthma exacerbation and peak expiratory flow rate (PEFR) less than 350 L/min were eligible. Exclusion criteria were need for intubation, chronic obstructive pulmonary disease, diabetes mellitus, insulinoma, pheochromocytoma, pregnancy, lactation, or current oral steroid treatment. Patients were randomly assigned to receive glucagon 0.03 mg/kg or an equivalent volume of saline solution intravenously. At 10 minutes, PEFR was measured and all patients began standardized albuterol therapy. Successful bronchodilation was a PEFR increase of 60 L/min at 10 minutes. RESULTS: Success occurred in 2 (9.5%) of 21 glucagon-treated patients and 3 (12%) of 25 placebo-treated patients (95% confidence interval [CI] for difference of -2.5% [-20.4% to 15. 4%]). Mean PEFR improvement for glucagon was 2 L/min versus 9 L/min for placebo (95% CI for difference of -7 L/min [-36 L/min to 23 L/min]). CONCLUSION: Glucagon alone provided no clinically important immediate bronchodilation in ED patients with asthma exacerbation.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1067/mem.2000.110823" target="_blank" rel="noreferrer noopener">10.1067/mem.2000.110823</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2000
Adult
Annals of emergency medicine
Asthma/complications/*drug therapy
Blanda M
Bronchodilator Agents/*administration & dosage
Department of Emergency Medicine
Double-Blind Method
Female
Gerson L W
Glucagon/*administration & dosage
Humans
Injections
Intravenous
Janas G
Male
Meerbaum S O
NEOMED College of Medicine
Wilber S T
Wilson J E